Reduce potential pharmacy fines and sanction activity.
DOWNLOAD TO LEARN MORE</a></h5>" /> DOWNLOAD TO LEARN MORE</a></h5>" />
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREArtificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREIQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSFederal efforts to curb prescription drug abuse and deaths have put pharmacies under tremendous pressure to verify prescriber credentials for hydrocodone combination products (HCPs), such as Vicodin, Lorcet and Lortab. Using data from OneKey Pharmacy Central Prescriber Validation, this report details the number of problematic DEA numbers, NPI numbers, OIG exclusions and inactive prescriber credentials that pharmacy customers saw from June to December 2016.
Under today’s environment of enforcement, however, pharmacies that fail to comply with regulatory requirements face serious consequences.
Changes in HCP prescription drug policies have been unfolding since 2004, when the U.S. Drug Enforcement Agency (DEA) first attempted to tighten restrictions. In 2013, recommendations by the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee (DSaRM) led to the 2014 reschedule. Since then, federal agencies and even Congress have given serious attention to the prevention of prescription opioid abuse and deaths, the latter of which reached historic numbers (more than 165,000) in 2014 .
Despite its decision in 2008 to keep HCPs classified as schedule III drugs, the U.S. Department of Health and Human Services (HHS) has now declared opioid prescription abuse and death a public health epidemic. Pharmacies are now being called on to be partners in the effort to combat opioid prescription drug abuse and deaths. To do so, pharmacies must ensure that their validation systems and processes are equipped to access the most up-to-date prescriber DEA data available.
With U.S. pharmacies filling more than 4 billion prescriptions every year, the ability to verify and validate prescriber credentials in a timely, efficient and accurate manner is not only vital for compliance but also for business.
As this pharmacy compliance report shows, pharmacies that fail to comply with the federal regulations governing Schedule II are subject to fines amounting to billions of dollars in just a six-month period. Additionally, failure to validate other data, including NPI numbers and OIG exclusions, can result in rejected reimbursements and withdrawals of payment.
The OneKey Central Prescriber Validation (CPV) solution provides modern pharmacies with a powerful, cost-effective and streamlined validation service to support current and future regulatory demands. The integration of OneKey CPV with QuintilesIMS, the largest healthcare data provider in the industry, has added a level of breadth that is unmatched in its capabilities and strength.
Reduce potential pharmacy fines and sanction activity.
Dominate key business areas with new business data and market views.